At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 505 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 3 clinical trial evaluating Bimekizumab and Placebo for Hidradenitis Suppurativa. Completed, enrolled 505 participants across 88 sites in 15 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesAustralia, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Spain, Switzerland, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionApr 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedJan 27, 2020
Enrollment StartFeb 19, 2020
Primary CompletionApr 7, 2022
Study CompletionFeb 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.4 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.
Placeboother
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.